Copy-number variants (CNVs) are a common finding in the human genome, with copy gains occurring at a higher frequency than losses in several databases of genomic variants in normal individuals. Copy gains of the steroid sulfatase (STS) gene have been seen in both males and females. Although deletion of STS in males is known to cause X-linked ichthyosis, the clinical significance of STS copy gains is less clear, with the duplication reported in individuals with abnormal phenotypes and normal relatives. We identified 72 males submitted to our laboratory for microarray-based comparative genomic hybridization with duplications in the STS region (chrX:6,465,812-8,093,195). In 40 (56%) patients, maternal blood was available, and the duplication was found to be inherited from the patient's apparently phenotypically normal mother in each of the 40 patients. We also identified three females who inherited a duplication of the STS region from phenotypically normal fathers, and a phenotypically normal uncle who had the same duplication as his nephews. In the remaining cases the inheritance could not be confirmed owing to lack of parental samples available for testing. Of the 72 subjects, 10 (14%) had an additional CNV elsewhere in the genome known to be clinically significant and likely causative of the patient's presenting symptoms. Based on the frequency with which duplications have been identified in clinically normal and abnormal individuals, we suggest a gain of STS in males is a population variant and unlikely to be clinically significant.
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, with the majority of cases being of precursor B-cell phenoltype. Conventional cytogenetic analysis plays an important role in the diagnosis of B-cell ALL, identifying characteristic chromosomal abnormalities associated with a given prognosis therein facilitating optimized treatment. The more recent introduction of microarray technology to the analysis of B-cell ALL has afforded both higher resolution for the detection of known abnormalities and an ability to identify novel copy number abnormalities (CNAs) with potential clinical relevance. In the current study, microarray analysis was performed on 20 cytogenetically abnormal B-cell ALL cases (10 pediatric and 10 adult), while a novel microarray-based balancedtranslocation detection methodology (translocation CGH or tCGH) was applied to that subset of cases with a known or suspected recurrent balanced translocation. Standard microarray analysis identified that CNAs was not detected by previous conventional cytogenetics in 75% (15/20) cases. tCGH identified 9/9 (100%) balanced translocations defining BCR/ABL1 (x4), ETV6/RUNX1 (x3), and MLL/AFF1 (x2) breakpoints with high resolution. The results illustrate the improved molecular detail afforded by these technologies and a comparison of translocation breakpoints, CNAs and patient age offers new insights into tumor biology with potential prognostic significance.
2529 The clinical heterogeneity of acute myeloid leukemia (AML) is well established and identification of specific balanced translocations is a critical component of the classification of AML. Patients with translocations are assigned to prognostic groups generally defined as good [e.g., t(8;21)(q22;q22), inv(16) (p13q22), t(15;17)(q24;q21)], intermediate [e.g., t(3;5)(q25;q34), t(9;11)(p22;q23)] and poor [e.g., other MLL translocations, inv(3)(q21q26.2), t(6;9)(p23;q34)]. Further refinement based on the identification of new genetic markers may help tailor prognostic and treatment decisions. In an effort to identify new molecular markers associated with recurrent translocations, we have analyzed 30 cases of AML with apparently balanced translocations using a microarray-based technology coupled with linear DNA amplification [translocation-CGH (tCGH)], providing high resolution mapping of translocation breakpoints and identification of copy number abnormalities at those breakpoints (BkPt-CNAs). Analysis can be multiplexed to interrogate 14 balanced translocations in a single test. Additionally, all cases were assayed by high-density aCGH to identify additional clinically relevant copy number abnormalities (CNAs) throughout the genome. For each sample these test results were compared. Patients were all adults (>40 years of age), 10 males and 20 females, and included t(15;17)(q24;q21) (8 cases), t(8;21) (q22;q22) (6 cases), inv(16)(p13q22) (5 cases), t(9;11)(p22;q23) (5 cases), t(3;5)(q25;q34) (4 cases), t(6;11)(q27;q23) (1 case) and t(6;9)(p23;q34) (1 case). Of the 30 cases, 6 showed BkPt-CNAs in one or both translocation partners. All 6 (100%) of these cases exhibited additional clinically relevant CNAs, whereas only 11/24 (46%) cases with no BkPt-CNAs showed additional CNAs. Thus, BkPt-CNAs are significantly correlated with the presence of secondary clinically relevant alterations (p=0.0208). Importantly, no MLL translocations cases revealed BkPt-CNAs. In contrast, 3 of 4 t(3;5)(q25;q34) cases showed BkPt-CNAs in both genes (NPM1 and MLF1) and additional CNAs, with two cases showing large deletions (>0.5 Mb) at both breakpoints. Alterations involved RSRC1 (mRNA splicing), FBXW11 (E3 ubiquitin protein ligase), STK10 (serine/threonine kinase), FGFR3 (growth factor receptor) and MGMT (O-6-methylguanine-DNA methyltransferase), findings potentially relevant to disease progression and treatment response. Cases of t(15;17), t(8;21) and inv(16) each showed a single case with BkPt-CNAs and these correlated with greater complexity for additional CNAs. For t(15;17), that case showed partial duplication of both the PML and RARA genes (47 kb and 39 kb) yielding a cryptic fusion (missed by karyotype and FISH) that produced the “long” form (bcr1) transcript based on the PML breakpoint and confirmed by rtPCR. This case also had a 24.56 Mb deletion at 13q14.2->q21.33 involving RB1, MIR15A and MIR16-1. In the 7 remaining PML-RARA cases [4 short (bcr3) and 3 long (bcr1)] with no BkPt-CNAs, two cases showed non-complex CNAs [(e.g., -Y (bcr1) or +8 (bcr3)]. Five of six t(8;21) cases exhibited CNAs, but the case with a BkPt-CNA (39 kb within RUNX1) exhibited greater complexity for CNAs (multiple gains and losses over >70 MB of distal 9q) than other cases (e.g., +8 or +15). Similarly, analysis of inv(16) cases demonstrated CNAs in 3 of 5 cases, with the greatest complexity in the case with BkPt-CNAs [deletion in CBFB and MYH11 involving ABCC1 (anion transporter implicated in multiple drug resistance), deletions 9q34.13 involving ABL1 and NUP214], while other cases had single changes of a homozygous deletion of GSTT1 or a heterozygous deletion of the 16p11.2 microdeletion syndrome region, either potentially inherited. The sole case of t(6;9) had only the relevant translocation. In conclusion, analysis of AML cases with balanced translocation by t-CGH and aCGH revealed significant correlation between BkPt-CNAs and the presence of secondary CNAs. Moreover, when BkPt-CNAs were present, the molecular complexity of additional CNAs was increased. This observation held true across various translocations evaluated, with the notable exception of MLL translocations. Thus BkPt-CNAs provide a broadly applicable signature for a subtle molecular instability in AML that, acquired or inherited, may predate translocations and may prove relevant to treatment response and outcome. Disclosures: Schultz: Signature Genomic Laboratories: Employment. Campbell:Abbott Molecular: Honoraria. Furrow:Signature Genomic Laboratories: Employment. Shaffer:Signature Genomic Laboratories: Employment. Ballif:Signature Genomic Laboratories: Employment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.